Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023

 Breaking News
  • No posts were found

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023

November 30
09:43 2023
Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023

DelveInsight’s, “Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline landscape. It covers the Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Report

  • DelveInsight’s Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Neoantigen-Based Personalized Cancer Therapeutic Vaccines treatment.
  • The leading companies working in the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market include OSE Immunotherapeutics, Neon Therapeutics, Inc. (BioNtech), Genocea Biosciences, Hangzhou Neoantigen Therapeutics, and others.
  • Promising Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Therapies in the various stages of development include Retifanlimab, Plasmid encoded IL-12, and others.
  • October 2023: Washington University School of Medicine announced a study of Phase 1 clinical trials for Retifanlimab. This study will test the hypothesis that a personalized neoantigen DNA vaccine in combination with concurrent administration of immune checkpoint blockade therapy will enhance the magnitude and breadth of neoantigen-specific T cell responses while maintaining an acceptable safety profile. The overall goal of this study is to identify the optimal vaccine plus adjuvant platform that can be tested in a subsequent phase II study to determine the efficacy of a personalized neoantigen vaccine approach in patients with GBM.

 

Request a sample and discover the recent advances in Neoantigen-Based Personalized Cancer Therapeutic Vaccines Treatment Drugs @ Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Report 

 

In the Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neoantigen-Based Personalized Cancer Therapeutic Vaccines collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Overview

Neoantigen-Based Personalized Cancer Therapeutic Vaccines has emerged as a new tumor immunotherapy approach for eliminating malignant tumors. Neoantigens are specific non-autologous proteins which are generated by non-synonymous mutations in tumorous cell genome. Neoantigens are highly immunogenic and are different from traditional tumor associated antigens (TAA) as they are not expressed in normal cells. These antigens can activate CD4+ and CD8+ T cells to generate immune response which have the potential to become new targets for tumor immunotherapy.

 

Find out more about Neoantigen-Based Personalized Cancer Therapeutic Vaccines Therapeutics Assessment @ Neoantigen-Based Personalized Cancer Therapeutic Vaccines Preclinical and Discovery Stage Products

 

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Emerging Drugs Profile

  • Tedopi (OSE2101): OSE Immunotherapeutics
  • NEO-PV-01: Neon Therapeutics, Inc. (BioNtech)

 

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Neoantigen-Based Personalized Cancer Therapeutic Vaccines. The Neoantigen-Based Personalized Cancer Therapeutic Vaccines companies which have their Neoantigen-Based Personalized Cancer Therapeutic Vaccines drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, OSE Immunotherapeutics and others.

 

DelveInsight’s Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Neoantigen-Based Personalized Cancer Therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

 

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

 

Learn more about the emerging Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Therapies @ Neoantigen-Based Personalized Cancer Therapeutic Vaccines Clinical Trials Assessment

 

Scope of the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Report

  • Coverage- Global
  • Neoantigen-Based Personalized Cancer Therapeutic Vaccines Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Neoantigen-Based Personalized Cancer Therapeutic Vaccines Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Neoantigen-Based Personalized Cancer Therapeutic Vaccines Companies- OSE Immunotherapeutics, Neon Therapeutics, Inc. (BioNtech), Genocea Biosciences, Hangzhou Neoantigen Therapeutics, and others.
  • Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline Therapies- Retifanlimab, Plasmid encoded IL-12, and others.

 

Dive deep into rich insights for new drugs for Neoantigen-Based Personalized Cancer Therapeutic Vaccines Treatment, Visit @ Neoantigen-Based Personalized Cancer Therapeutic Vaccines Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Neoantigen-Based Personalized Cancer Therapeutic Vaccines: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Neoantigen-Based Personalized Cancer Therapeutic Vaccines – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Neoantigen-Based Personalized Cancer Therapeutic Vaccines Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Tedopi (OSE2101): OSE Immunotherapeutics
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. NEO-PV-01: Neon Therapeutics, Inc. (BioNtech)
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Neoantigen-Based Personalized Cancer Therapeutic Vaccines Key Companies
  19. Neoantigen-Based Personalized Cancer Therapeutic Vaccines Key Products
  20. Neoantigen-Based Personalized Cancer Therapeutic Vaccines- Unmet Needs
  21. Neoantigen-Based Personalized Cancer Therapeutic Vaccines- Market Drivers and Barriers
  22. Neoantigen-Based Personalized Cancer Therapeutic Vaccines- Future Perspectives and Conclusion
  23. Neoantigen-Based Personalized Cancer Therapeutic Vaccines Analyst Views
  24. Neoantigen-Based Personalized Cancer Therapeutic Vaccines Key Companies
  25. Appendix

 

For further information on the Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline therapeutics, reach out to Neoantigen-Based Personalized Cancer Therapeutic Vaccines Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market

Related Articles

Categories